Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Lifting the mask: identification of new small molecule inhibitors of uropathogenic Escherichia coli group 2 capsule biogenesis.

Goller CC, Arshad M, Noah JW, Ananthan S, Evans CW, Nebane NM, Rasmussen L, Sosa M, Tower NA, White EL, Neuenswander B, Porubsky P, Maki BE, Rogers SA, Schoenen F, Seed PC.

PLoS One. 2014 Jul 1;9(7):e96054. doi: 10.1371/journal.pone.0096054. eCollection 2014.

2.

Threading the Needle: Small-Molecule Targeting of a Xenobiotic Receptor to Ablate Escherichia coli Polysaccharide Capsule Expression Without Altering Antibiotic Resistance.

Arshad M, Goller CC, Pilla D, Schoenen FJ, Seed PC.

J Infect Dis. 2016 Apr 15;213(8):1330-9. doi: 10.1093/infdis/jiv584. Epub 2015 Dec 15.

3.

3-(2,6-difluorobenzamido)-5-(4-ethoxyphenyl) thiophene-2-carboxylic acid inhibits E.coli UT189 bacterial capsule biogenesis.

Noah JW, Ananthan S, Evans CW, Nebane NM, Rasmussen L, Sosa M, Tower NA, White EL, Seed P, Goller C, Datta A, Neuenswander B, Porubsky P, Maki BE, Rogers SA, Schoenen F, Aubé J.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Apr 16 [updated 2013 Mar 14].

4.

N-(pyridin-4-yl)benzo[d]thiazole-6-carboxamide inhibits E. coli UT189 bacterial capsule biogenesis.

Noah JW, Ananthan S, Evans CW, Nebane NM, Rasmussen L, Sosa M, Tower NA, White EL, Seed P, Goller C, Arshad M, Datta A, Neuenswander B, Porubsky P, Maki BE, Liu C, Rogers SA, Schoenen F, Aubé J.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 17 [updated 2013 Apr 5].

5.

Oral supplementation of trans-cinnamaldehyde reduces uropathogenic Escherichia coli colonization in a mouse model.

Narayanan A, Muyyarikkandy MS, Mooyottu S, Venkitanarayanan K, Amalaradjou MA.

Lett Appl Microbiol. 2017 Mar;64(3):192-197. doi: 10.1111/lam.12713. Epub 2017 Jan 28.

PMID:
28063174
6.

Inhibitors of TonB function identified by a high-throughput screen for inhibitors of iron acquisition in uropathogenic Escherichia coli CFT073.

Yep A, McQuade T, Kirchhoff P, Larsen M, Mobley HL.

MBio. 2014 Feb 25;5(2):e01089-13. doi: 10.1128/mBio.01089-13.

7.
8.

Role of capsule and O antigen in the virulence of uropathogenic Escherichia coli.

Sarkar S, Ulett GC, Totsika M, Phan MD, Schembri MA.

PLoS One. 2014 Apr 10;9(4):e94786. doi: 10.1371/journal.pone.0094786. eCollection 2014.

9.

Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.

Blango MG, Mulvey MA.

Antimicrob Agents Chemother. 2010 May;54(5):1855-63. doi: 10.1128/AAC.00014-10. Epub 2010 Mar 15.

10.

Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice.

Guiton PS, Cusumano CK, Kline KA, Dodson KW, Han Z, Janetka JW, Henderson JP, Caparon MG, Hultgren SJ.

Antimicrob Agents Chemother. 2012 Sep;56(9):4738-45. doi: 10.1128/AAC.00447-12. Epub 2012 Jun 25.

11.

Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis.

Anderson GG, Goller CC, Justice S, Hultgren SJ, Seed PC.

Infect Immun. 2010 Mar;78(3):963-75. doi: 10.1128/IAI.00925-09. Epub 2010 Jan 19.

12.

Uropathogenic Escherichia coli mediated urinary tract infection.

Totsika M, Moriel DG, Idris A, Rogers BA, Wurpel DJ, Phan MD, Paterson DL, Schembri MA.

Curr Drug Targets. 2012 Oct;13(11):1386-99.

PMID:
22664092
13.

Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection.

Brumbaugh AR, Smith SN, Mobley HL.

Infect Immun. 2013 Sep;81(9):3309-16. doi: 10.1128/IAI.00470-13. Epub 2013 Jun 24.

14.

Intramacrophage survival of uropathogenic Escherichia coli: differences between diverse clinical isolates and between mouse and human macrophages.

Bokil NJ, Totsika M, Carey AJ, Stacey KJ, Hancock V, Saunders BM, Ravasi T, Ulett GC, Schembri MA, Sweet MJ.

Immunobiology. 2011 Nov;216(11):1164-71. doi: 10.1016/j.imbio.2011.05.011. Epub 2011 May 24.

PMID:
21802164
15.

High-throughput identification of chemical inhibitors of E. coli Group 2 capsule biogenesis as anti-virulence agents.

Goller CC, Seed PC.

PLoS One. 2010 Jul 19;5(7):e11642. doi: 10.1371/journal.pone.0011642.

16.

Kinetics of uropathogenic Escherichia coli metapopulation movement during urinary tract infection.

Walters MS, Lane MC, Vigil PD, Smith SN, Walk ST, Mobley HL.

MBio. 2012 Feb 7;3(1). pii: e00303-11. doi: 10.1128/mBio.00303-11. Print 2012.

17.

Surfactant protein D inhibits adherence of uropathogenic Escherichia coli to the bladder epithelial cells and the bacterium-induced cytotoxicity: a possible function in urinary tract.

Kurimura Y, Nishitani C, Ariki S, Saito A, Hasegawa Y, Takahashi M, Hashimoto J, Takahashi S, Tsukamoto T, Kuroki Y.

J Biol Chem. 2012 Nov 16;287(47):39578-88. doi: 10.1074/jbc.M112.380287. Epub 2012 Sep 25.

18.

Uropathogenic Escherichia coli virulence and innate immune responses during urinary tract infection.

Ulett GC, Totsika M, Schaale K, Carey AJ, Sweet MJ, Schembri MA.

Curr Opin Microbiol. 2013 Feb;16(1):100-7. doi: 10.1016/j.mib.2013.01.005. Epub 2013 Feb 8. Review.

PMID:
23403118
19.

Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation.

Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, Aberg V, Walker JN, Seed PC, Almqvist F, Chapman MR, Hultgren SJ.

Nat Chem Biol. 2009 Dec;5(12):913-9. doi: 10.1038/nchembio.242. Epub 2009 Oct 25.

20.

Supplemental Content

Support Center